D. E. Sousa-mendes-maïlys, . Deborah, . Vinot-cécile, and . Valade-elodie,

P. Gabrielle, . Claire, . Bouazza-naïm, and . Frantz,

P. Stephane, . Gilles, . Jean-marc, and . Saik#, BENABOUD Sihem# #Ces auteurs ont contribués également à l'encadrement de la rédaction du manuscrit Article publié dans le journal, British Journal of Clinical Pharmacology, 2016.

, Poster présenté :-PAGE meeting, Hersonissos, juin 2015-GMP meeting, 2015.

, Présentation orale :-GMP meeting, 2015.

J. R. Daw, G. E. Hanley, D. L. Greyson, and S. G. Morgan, Prescription drug use during pregnancy in developed countries: a systematic review, Pharmacoepidemiol Drug Saf, vol.20, issue.9, pp.895-902, 2011.

F. Staud and M. Ceckova, Regulation of drug transporter expression and function in the placenta, Expert Opin Drug Metab Toxicol, vol.11, issue.4, pp.533-55, 2015.

A. B. Ke, A. Rostami-hodjegan, P. Zhao, and J. D. Unadkat, Pharmacometrics in Pregnancy: An Unmet Need, Annu Rev Pharmacol Toxicol, vol.54, issue.1, pp.53-69, 2014.

J. Caldwell, I. Gardner, and N. Swales, An introduction to drug disposition: the basic principles of absorption, distribution, metabolism, and excretion, Toxicol Pathol, vol.23, issue.2, pp.102-116, 1995.

R. R. Levine, Factors affecting gastrointestinal absorption of drugs, Am J Dig Dis, vol.15, issue.2, pp.171-188, 1970.

T. Rodgers, D. Leahy, and M. Rowland, Physiologically based pharmacokinetic modeling 1: Predicting the tissue distribution of moderate-to-strong bases, J Pharm Sci, vol.94, issue.6, pp.1259-76, 2005.

U. M. Zanger and M. Schwab, Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation, Pharmacol Ther, vol.138, issue.1, pp.103-144, 2013.

J. C. Stingl, J. Brockmöller, and R. Viviani, Genetic variability of drug-metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain function, Mol Psychiatry, vol.18, issue.3, pp.273-87, 2013.

C. D. Klaassen, L. M. Aleksunes, and . Xenobiotic, Bile Acid, and Cholesterol Transporters: Function and Regulation, Pharmacol Rev, vol.62, issue.1, pp.1-96, 2010.

S. Vozeh, J. L. Steimer, M. Rowland, P. Morselli, F. Mentre et al., The use of population pharmacokinetics in drug development, Clin Pharmacokinet, vol.30, issue.2, pp.81-93, 1996.

N. Simon, Pharmacocinétique de Population Introduction à Nonmem. SOLAL Editeurs, 2006.

M. M. Costantine, Physiologic and pharmacokinetic changes in pregnancy, Front Pharmacol, vol.5, p.65, 2014.

K. Abduljalil, P. Furness, T. N. Johnson, A. Rostami-hodjegan, and H. Soltani, Anatomical, physiological and metabolic changes with gestational age during normal pregnancy: a database for parameters required in physiologically based pharmacokinetic modelling, Clin Pharmacokinet, vol.51, issue.6, pp.365-96, 2012.

O. Sullivan, G. M. Bullingham, and R. E. , The assessment of gastric acidity and antacid effect in pregnant women by a non-invasive radiotelemetry technique, Br J Obstet Gynaecol, vol.91, issue.10, pp.973-981, 1984.

O. Sullivan, G. M. Sutton, A. J. Thompson, S. A. Carrie, L. E. Bullingham et al., Noninvasive measurement of gastric emptying in obstetric patients, Anesth Analg, vol.66, issue.6, pp.505-516, 1987.

M. Chiloiro, G. Darconza, E. Piccioli, M. De-carne, C. Clemente et al., Gastric emptying and orocecal transit time in pregnancy, J Gastroenterol, vol.36, issue.8, pp.538-581, 2001.

J. Wilson, Gastric emptying in labour: some recent findings and their clinical significance, J Int Med Res, vol.6, issue.1, pp.54-62, 1978.

M. C. Kelly, U. A. Carabine, D. A. Hill, and R. K. Mirakhur, A comparison of the effect of intrathecal and extradural fentanyl on gastric emptying in laboring women, Anesth Analg, vol.85, issue.4, pp.834-842, 1997.

D. Mosha, M. Guidi, F. Mwingira, S. Abdulla, T. Mercier et al., Population Pharmacokinetics and Clinical Response for Artemether-Lumefantrine in Pregnant and Nonpregnant Women with Uncomplicated Plasmodium falciparum Malaria in Tanzania, Antimicrob Agents Chemother, vol.58, issue.8, pp.4583-92, 2014.

A. B. Ke, S. C. Nallani, P. Zhao, A. Rostami-hodjegan, and J. D. Unadkat, A PBPK Model to Predict Disposition of CYP3A-Metabolized Drugs in Pregnant Women: Verification and Discerning the Site of CYP3A Induction, CPT Pharmacomet Syst Pharmacol, vol.1, issue.9, p.3, 2012.

M. Dawes and P. J. Chowienczyk, Pharmacokinetics in pregnancy, Best Pract Res Clin Obstet Gynaecol, vol.15, issue.6, pp.819-845, 2001.

T. Tomson, U. Lindbom, B. Ekqvist, and A. Sundqvist, Epilepsy and Pregnancy: A Prospective Study of Seizure Control in Relation to Free and Total Plasma Concentrations of Carbamazepine and Phenytoin, Epilepsia, vol.35, issue.1, pp.122-152, 1994.

G. R. Wilkinson and D. G. Shand, Commentary: a physiological approach to hepatic drug clearance, Clin Pharmacol Ther, vol.18, issue.4, pp.377-90, 1975.

J. F. Clapp, W. Stepanchak, J. Tomaselli, M. Kortan, and S. Faneslow, Portal vein blood flow-Effects of pregnancy, gravity, and exercise, Am J Obstet Gynecol, vol.183, issue.1, pp.167-72, 2000.

C. Fotopoulou, R. Kretz, S. Bauer, J. C. Schefold, B. Schmitz et al., Prospectively assessed changes in lamotrigine-concentration in women with epilepsy during pregnancy, lactation and the neonatal period, Epilepsy Res, vol.85, issue.1, pp.60-64, 2009.

J. H. Fischer, G. E. Sarto, J. Hardman, L. Endres, T. M. Jenkins et al., Influence of gestational age and body weight on the pharmacokinetics of labetalol in pregnancy, Clin Pharmacokinet, vol.53, issue.4, pp.373-83, 2014.

A. B. Ke, S. C. Nallani, P. Zhao, A. Rostami-hodjegan, N. Isoherranen et al., A physiologically based pharmacokinetic model to predict disposition of CYP2D6 and CYP1A2 metabolized drugs in pregnant women, Drug Metab Dispos Biol Fate Chem, vol.41, issue.4, pp.801-814, 2013.

L. Gaohua, K. Abduljalil, M. Jamei, T. N. Johnson, and A. Rostami-hodjegan, A pregnancy physiologically based pharmacokinetic (p-PBPK) model for disposition of drugs metabolized by CYP1A2, CYP2D6 and CYP3A4, Br J Clin Pharmacol, vol.74, issue.5, pp.873-85, 2012.

A. B. Ke, S. C. Nallani, P. Zhao, A. Rostami-hodjegan, and J. D. Unadkat, Expansion of a PBPK model to predict disposition in pregnant women of drugs cleared via multiple CYP enzymes, including CYP2B6, CYP2C9 and CYP2C19, Br J Clin Pharmacol, vol.77, issue.3, pp.554-70, 2014.

D. E. Zaske, R. J. Cipolle, R. G. Strate, J. W. Malo, and M. F. Koszalka, Rapid gentamicin elimination in obstetric patients, Obstet Gynecol, vol.56, issue.5, pp.559-64, 1980.

D. J. Morgan, Drug disposition in mother and foetus, Clin Exp Pharmacol Physiol, vol.24, issue.11, pp.869-73, 1997.

C. Prouillac and S. Lecoeur, The Role of the Placenta in Fetal Exposure to Xenobiotics: Importance of Membrane Transporters and Human Models for Transfer Studies, Drug Metab Dispos, vol.38, issue.10, pp.1623-1658, 2010.

, Encyclopédie Larousse en ligne-grossesse, 2015.

P. Myllynen and K. Vähäkangas, Placental transfer and metabolism: An overview of the experimental models utilizing human placental tissue, Toxicol In Vitro, vol.27, issue.1, pp.507-519, 2013.

L. Mandelbrot, G. Peytavin, G. Firtion, and R. Farinotti, Maternal-fetal transfer and amniotic fluid accumulation of lamivudine in human immunodeficiency virus-infected pregnant women, Am J Obstet Gynecol, vol.184, issue.2, pp.153-161, 2001.

P. Berveiller, O. Mir, C. Vinot, C. Bonati, P. Duchene et al., Transplacental transfer of oseltamivir and its metabolite using the human perfused placental cotyledon model, Am J Obstet Gynecol, vol.206, issue.1, pp.92-93, 2012.

L. Gavard, S. Gil, G. Peytavin, P. Ceccaldi, C. Ferreira et al., Placental transfer of lopinavir/ritonavir in the ex vivo human cotyledon perfusion model, Am J Obstet Gynecol, vol.195, issue.1, pp.296-301, 2006.

F. Forestier, P. De-renty, G. Peytavin, E. Dohin, R. Farinotti et al., Maternal-fetal transfer of saquinavir studied in the ex vivo placental perfusion model, Am J Obstet Gynecol, vol.185, issue.1, pp.178-81, 2001.

T. Heikkinen, U. Ekblad, and K. Laine, Transplacental transfer of citalopram, fluoxetine and their primary demethylated metabolites in isolated perfused human placenta, BJOG Int J Obstet Gynaecol, vol.109, issue.9, pp.1003-1008, 2002.

T. Heikkinen, U. Ekblad, and K. Laine, Transplacental transfer of amitriptyline and nortriptyline in isolated perfused human placenta, Psychopharmacology (Berl), vol.153, issue.4, pp.450-454, 2001.

D. Hirt, S. Urien, E. Rey, E. Arrive, D. K. Ekouevi et al., Population Pharmacokinetics of Emtricitabine in Human Immunodeficiency Virus Type 1-Infected Pregnant Women and Their Neonates, Antimicrob Agents Chemother, vol.53, issue.3, pp.1067-73, 2008.
URL : https://hal.archives-ouvertes.fr/inserm-00348223

F. Fauchet, J. Treluyer, P. Frange, S. Urien, F. Foissac et al., Population Pharmacokinetics Study of Recommended Zidovudine Doses in HIV-1-Infected Children, Antimicrob Agents Chemother, vol.57, issue.10, pp.4801-4809, 2013.

S. Benaboud, J. M. Treluyer, S. Urien, S. Blanche, N. Bouazza et al., Pregnancy-Related Effects on Lamivudine Pharmacokinetics in a Population Study with 228 Women, Antimicrob Agents Chemother, vol.56, issue.2, pp.776-82, 2012.

D. Hirt, S. Urien, D. K. Ekouévi, E. Rey, E. Arrivé et al., Population pharmacokinetics of tenofovir in HIV-1-infected pregnant women and their neonates (ANRS 12109), Clin Pharmacol Ther, vol.85, issue.2, pp.182-191, 2009.

T. Kiserud, C. Ebbing, J. Kessler, and S. Rasmussen, Fetal cardiac output, distribution to the placenta and impact of placental compromise, Ultrasound Obstet Gynecol, vol.28, issue.2, pp.126-162, 2006.

M. A. Underwood, W. M. Gilbert, and M. P. Sherman, Amniotic Fluid: Not Just Fetal Urine Anymore, J Perinatol, vol.25, issue.5, pp.341-349, 2005.

M. H. Beall, J. Van-den-wijngaard, M. Van-gemert, and M. G. Ross, Amniotic Fluid Water Dynamics, Placenta, vol.28, issue.8-9, pp.816-839, 2007.

M. Heller and L. Burd, Review of ethanol dispersion, distribution, and elimination from the fetal compartment, Birt Defects Res A Clin Mol Teratol, vol.100, issue.4, pp.277-83, 2014.

A. Bs, Developmental patterns of renal functional maturation compared in the human neonate, J Pediatr, vol.92, issue.5, pp.705-717, 1978.

S. Alqahtani and A. Kaddoumi, Development of Physiologically Based Pharmacokinetic/Pharmacodynamic Model for Indomethacin Disposition in, PLOS ONE, vol.10, issue.10, p.139762, 2015.

S. Pilari, C. Preuße, and W. Huisinga, Gestational influences on the pharmacokinetics of gestagenic drugs: A combined in silico, in vitro and in vivo analysis, Eur J Pharm Sci, vol.42, issue.4, pp.318-349, 2011.

B. Xia, T. Heimbach, R. Gollen, C. Nanavati, and H. He, A Simplified PBPK Modeling Approach for Prediction of Pharmacokinetics of Four Primarily Renally Excreted and CYP3A Metabolized Compounds During Pregnancy, AAPS J, vol.15, issue.4, pp.1012-1036, 2013.

S. Eyal, T. R. Easterling, D. Carr, J. G. Umans, M. Miodovnik et al., Pharmacokinetics of Metformin during Pregnancy, Drug Metab Dispos, vol.38, issue.5, pp.833-873, 2010.

P. R. Gentry, T. R. Covington, M. E. Andersen, I. Clewell, and . Hj, Application of a Physiologically Based Pharmacokinetic Model for Isopropanol in the Derivation of a Reference Dose and Reference Concentration, Regul Toxicol Pharmacol, vol.36, issue.1, pp.51-68, 2002.

W. Maruyama, K. Yoshida, T. Tanaka, and J. Nakanishi, Simulation of dioxin accumulation in human tissues and analysis of reproductive risk, Chemosphere, vol.53, issue.4, pp.301-314, 2003.

M. L. Gargas, T. R. Tyler, L. M. Sweeney, R. A. Corley, K. K. Weitz et al., A toxicokinetic study of inhaled ethylene glycol monomethyl ether (2-ME) and validation of a physiologically based pharmacokinetic model for the pregnant rat and human, Toxicol Appl Pharmacol, vol.165, issue.1, pp.53-62, 2000.

T. S. Poet, C. R. Kirman, M. Bader, C. Thriel, . Van et al., Quantitative Risk Analysis for NMethyl Pyrrolidone Using Physiologically Based Pharmacokinetic and Benchmark Dose Modeling, Toxicol Sci, vol.113, issue.2, pp.468-82, 2010.

M. Verner, P. Ayotte, G. Muckle, M. Charbonneau, and S. Haddad, A physiologically based pharmacokinetic model for the assessment of infant exposure to persistent organic pollutants in epidemiologic studies, Environ Health Perspect, vol.117, issue.3, p.481, 2009.

A. Lumen, D. R. Mattie, and J. W. Fisher, Evaluation of Perturbations in Serum Thyroid Hormones During Human Pregnancy Due to Dietary Iodide and Perchlorate Exposure Using a Biologically Based Dose-Response Model, Toxicol Sci, vol.133, issue.2, pp.320-361, 2013.

M. Verner, A. E. Loccisano, N. Morken, M. Yoon, H. Wu et al., Associations of Perfluoroalkyl Substances (PFAS) with Lower Birth Weight: An Evaluation of Potential Confounding by Glomerular Filtration Rate Using a Physiologically Based Pharmacokinetic Model (PBPK). Environ Health Perspect, vol.123, pp.1317-1341, 2015.

A. E. Loccisano, M. P. Longnecker, J. L. Campbell, and M. E. Andersen, Clewell HJ 3rd. Development of PBPK models for PFOA and PFOS for human pregnancy and lactation life stages, J Toxicol Environ Health A, vol.76, issue.1, pp.25-57, 2013.

R. H. Luecke, W. D. Wosilait, B. A. Pearce, and J. F. Young, A computer model and program for xenobiotic disposition during pregnancy, Comput Methods Programs Biomed, vol.53, issue.3, pp.201-224, 1997.

R. H. Luecke, W. D. Wosilait, and J. F. Young, Mathematical representation of organ growth in the human embryo/fetus, Int J Biomed Comput, vol.39, issue.3, pp.337-384, 1995.

M. Yoon, J. D. Schroeter, A. Nong, M. D. Taylor, D. C. Dorman et al., Physiologically Based Pharmacokinetic Modeling of Fetal and Neonatal Manganese Exposure in Humans: Describing Manganese Homeostasis during Development, Toxicol Sci, vol.122, issue.2, pp.297-316, 2011.

B. S. Shin, S. W. Hwang, J. B. Bulitta, J. B. Lee, S. D. Yang et al., Assessment of bisphenol A exposure in Korean pregnant women by physiologically based pharmacokinetic modeling, J Toxicol Environ Health A, vol.73, pp.1586-98, 2010.

G. Lu, K. Abduljalil, M. Jamei, T. N. Johnson, H. Soltani et al., Physiologically-based pharmacokinetic (PBPK) models for assessing the kinetics of xenobiotics during pregnancy: achievements and shortcomings, Curr Drug Metab, vol.13, issue.6, pp.695-720, 2012.

R. H. Luecke, W. D. Wosilait, B. A. Pearce, and J. F. Young, A physiologically based pharmacokinetic computer model for human pregnancy, Teratology, vol.49, issue.2, pp.90-103, 1994.

L. M. Sweeney, C. R. Kirman, S. A. Gannon, K. D. Thrall, M. L. Gargas et al., Development of a physiologically based pharmacokinetic (PBPK) model for methyl iodide in rats, rabbits, and humans, Inhal Toxicol, vol.21, issue.6, pp.552-82, 2009.

K. Shintaku, S. Hori, H. Satoh, K. Tsukimori, H. Nakano et al., Prediction and evaluation of fetal toxicity induced by NSAIDs using transplacental kinetic parameters obtained from human placental perfusion studies, Br J Clin Pharmacol, vol.73, issue.2, pp.248-56, 2012.

B. P. Kearney, J. F. Flaherty, and J. Shah, Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics, Clin Pharmacokinet, vol.43, issue.9, pp.595-612, 2004.

, Gilead Sciences, Inc. Product Information: Emtriva(TM), emtricitabine capsules, 2003.

R. Glaxosmithkline and . Park, Product Information: Epivir(R), lamivudine, 2002.

A. K. Pau and J. M. George, Antiretroviral therapy: current drugs, Infect Dis Clin North Am, vol.28, issue.3, pp.371-402, 2014.

, ViiV Healthcare Shire Canada. monographie Heptovir,lamivudine, 2011.

P. Fan-havard, Z. Liu, M. Chou, Y. Ling, A. Barrail-tran et al., Pharmacokinetics of Phase I Nevirapine Metabolites following a Single Dose and at Steady State, Antimicrob Agents Chemother, vol.57, issue.5, pp.2154-60, 2013.

M. J. Lamson, J. P. Sabo, T. R. Macgregor, J. W. Pav, L. Rowland et al., Single dose pharmacokinetics and bioavailability of nevirapine in healthy volunteers, Biopharm Drug Dispos, vol.20, issue.6, pp.285-91, 1999.

O. Janneh and S. Khoo, Interactions of Tenofovir, Lamivudine, Abacavir and Didanosine in Primary Human Cells, Pharmaceutics, vol.3, issue.4, pp.326-363, 2011.

M. Ibarra, M. Vázquez, and P. Fagiolino, Population pharmacokinetic model to analyze nevirapine multiple-peaks profile after a single oral dose, J Pharmacokinet Pharmacodyn, vol.41, issue.4, pp.363-73, 2014.

, Product Information: VIREAD(R) oral tablets, tenofovir disoproxil fumarate oral tablets, 2010.

S. Benaboud, D. Hirt, O. Launay, E. Pannier, G. Firtion et al., Pregnancy-Related Effects on Tenofovir Pharmacokinetics: a Population Study with 186 Women, Antimicrob Agents Chemother, vol.56, issue.2, pp.857-62, 2011.

W. A. Lee, G. He, E. Eisenberg, T. Cihlar, S. Swaminathan et al., Selective Intracellular Activation of a Novel Prodrug of the Human Immunodeficiency Virus Reverse Transcriptase Inhibitor Tenofovir Leads to Preferential Distribution and Accumulation in Lymphatic Tissue, Antimicrob Agents Chemother, vol.49, issue.5, pp.1898-906, 2005.

M. A. Johnson, K. H. Moore, G. J. Yuen, A. Bye, and G. E. Pakes, Clinical pharmacokinetics of lamivudine, Clin Pharmacokinet, vol.36, issue.1, pp.41-66, 1999.

Y. S. Cramer, S. L. Rosenkranz, S. D. Hall, L. A. Szczech, V. Amorosa et al., Hemodialysis Does Not Significantly Affect the Pharmacokinetics of Nevirapine in HIV-1-Infected Persons Requiring Hemodialysis: Results From ACTG A5177, JAIDS J Acquir Immune Defic Syndr, vol.54, issue.4, pp.7-9, 2010.

A. S. Ray, T. Cihlar, K. L. Robinson, L. Tong, J. E. Vela et al., Mechanism of Active Renal Tubular Efflux of Tenofovir, Antimicrob Agents Chemother, vol.50, issue.10, pp.3297-304, 2006.

T. Cihlar, G. Laflamme, R. Fisher, A. C. Carey, J. E. Vela et al., Novel Nucleotide Human Immunodeficiency Virus Reverse Transcriptase Inhibitor GS-9148 with a Low Nephrotoxic Potential: Characterization of Renal Transport and Accumulation, Antimicrob Agents Chemother, vol.53, issue.1, pp.150-156, 2008.

N. Jung, C. Lehmann, A. Rubbert, M. Knispel, P. Hartmann et al., Relevance of the Organic Cation Transporters 1 and 2 for Antiretroviral Drug Therapy in Human Immunodeficiency Virus Infection, Drug Metab Dispos, vol.36, issue.8, pp.1616-1639, 2008.

J. De-souza, L. Z. Benet, Y. Huang, and S. Storpirtis, Comparison of bidirectional lamivudine and zidovudine transport using MDCK, MDCK-MDR1, and Caco-2 cell monolayers, J Pharm Sci, vol.98, issue.11, pp.4413-4422, 2009.

G. Minuesa, C. Volk, M. Molina-arcas, V. Gorboulev, I. Erkizia et al., Transport of Lamivudine [(-)-L-2',3'-Dideoxy-3'-thiacytidine] and HighAffinity Interaction of Nucleoside Reverse Transcriptase Inhibitors with Human Organic Cation Transporters 1, 2, and 3, J Pharmacol Exp Ther, vol.329, issue.1, pp.252-61, 2009.

F. Müller, J. König, E. Hoier, K. Mandery, and M. F. Fromm, Role of organic cation transporter OCT2 and multidrug and toxin extrusion proteins MATE1 and MATE2-K for transport and drug interactions of the antiviral lamivudine, Biochem Pharmacol, vol.86, issue.6, pp.808-823, 2013.

L. Bousquet, A. Pruvost, N. Didier, R. Farinotti, A. Mabondzo et al., Inhibitor and substrate of multidrug resistance associated protein, Eur J Pharm Sci, vol.35, issue.4, pp.247-56, 2008.

V. Michaud, T. Bar-magen, J. Turgeon, D. Flockhart, Z. Desta et al., The Dual Role of Pharmacogenetics in HIV Treatment: Mutations and Polymorphisms Regulating Antiretroviral Drug Resistance and Disposition, Pharmacol Rev, vol.64, issue.3, pp.803-836, 2012.

N. J. Liptrott, S. Pushpakom, C. Wyen, G. Fätkenheuer, C. Hoffmann et al., German Competence Network for HIV/AIDS. Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS, Pharmacogenet Genomics, vol.22, issue.1, pp.10-19, 2012.

S. G. Deeks, P. Barditch-crovo, P. S. Lietman, F. Hwang, K. C. Cundy et al., (R)(Phosphonomethoxy)propyl]adenine, a Novel Anti-Human Immunodeficiency Virus (HIV) Therapy, in HIVInfected Adults, Pharmacokinetics, and Antiretroviral Activity of Intravenous 9, vol.42, p.2380, 1998.

R. Van-leeuwen, J. M. Lange, E. K. Hussey, K. H. Donn, S. T. Hall et al., The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection: a phase I study, AIDS Lond Engl, vol.6, issue.12, pp.1471-1476, 1992.

J. L. Campbell, R. A. Clewell, P. R. Gentry, M. E. Andersen, and H. J. Clewell, Physiologically Based Pharmacokinetic/Toxicokinetic Modeling, Computational Toxicology, pp.439-99, 2009.

P. S. Price, R. B. Conolly, C. F. Chaisson, E. A. Gross, J. S. Young et al., Modeling Interindividual Variation in Physiological Factors Used in PBPK Models of Humans, Crit Rev Toxicol, vol.33, issue.5, pp.469-503, 2003.

A. M. Peters, L. Perry, C. A. Hooker, B. Howard, M. Neilly et al., Extracellular fluid volume and glomerular filtration rate in 1878 healthy potential renal transplant donors: effects of age, gender, obesity and scaling, Nephrol Dial Transplant, vol.27, issue.4, pp.1429-1466, 2012.

T. Rodgers and M. Rowland, Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions, J Pharm Sci, vol.95, issue.6, pp.1238-57, 2006.

D. Mascio, M. Srinivasula, S. Bhattacharjee, A. Cheng, L. Martiniova et al., Antiretroviral Tissue Kinetics: In Vivo Imaging Using Positron Emission Tomography, Antimicrob Agents Chemother, vol.53, issue.10, pp.4086-95, 2009.

T. Imaoka, H. Kusuhara, M. Adachi, J. D. Schuetz, K. Takeuchi et al., Functional Involvement of Multidrug Resistance-Associated Protein 4 (MRP4/ABCC4) in the Renal Elimination of the Antiviral Drugs Adefovir and Tenofovir, Mol Pharmacol, vol.71, issue.2, pp.619-646, 2007.

D. M. Klein, K. K. Evans, R. N. Hardwick, W. H. Dantzler, S. H. Wright et al., Basolateral uptake of nucleosides by Sertoli cells is mediated primarily by equilibrative nucleoside transporter 1, J Pharmacol Exp Ther, vol.346, issue.1, pp.121-130, 2013.

R. G. Gish, N. Leung, T. L. Wright, H. Trinh, W. Lang et al., Dose Range Study of Pharmacokinetics, Safety, and Preliminary Antiviral Activity of Emtricitabine in Adults with Hepatitis B Virus Infection, Antimicrob Agents Chemother, vol.46, issue.6, pp.1734-1774, 2002.

P. Riska, M. Lamson, T. Macgregor, J. Sabo, S. Hattox et al., Disposition and biotransformation of the antiretroviral drug nevirapine in humans, Drug Metab Dispos Biol Fate Chem, vol.27, issue.8, pp.895-901, 1999.

M. Lamson, T. Macgregor, P. Riska, D. Erickson, P. Maxfield et al., Nevirapine induces both CYP3A4 and CYP2B6 metabolic pathways, Clin Pharmacol Ther, vol.65, issue.2, pp.137-137, 1999.

D. A. Erickson, G. Mather, W. F. Trager, R. H. Levy, and J. J. Keirns, Characterization of the In Vitro Biotransformation of the HIV-1 Reverse Transcriptase Inhibitor Nevirapine by Human Hepatic Cytochromes P-450, Drug Metab Dispos, vol.27, issue.12, pp.1488-95, 1999.

L. A. Wenning, E. J. Friedman, J. T. Kost, S. A. Breidinger, J. E. Stek et al., Lack of a Significant Drug Interaction between Raltegravir and Tenofovir, Antimicrob Agents Chemother, vol.52, issue.9, pp.3253-3261, 2008.
DOI : 10.1128/aac.00005-08

URL : https://aac.asm.org/content/52/9/3253.full.pdf

L. H. Wang, J. Begley, S. Claire-rl-3rd, J. Harris, C. Wakeford et al., Pharmacokinetic and pharmacodynamic characteristics of emtricitabine support its once daily dosing for the treatment of HIV infection, AIDS Res Hum Retroviruses, vol.20, issue.11, pp.1173-82, 2004.

J. Moltó, M. Valle, C. Miranda, S. Cedeño, J. Miranda et al., Onceor twice-daily dosing of nevirapine in HIV-infected adults: a population pharmacokinetics approach, J Antimicrob Chemother, vol.62, issue.4, pp.784-92, 2008.

R. Mallants, K. Van-oosterwyck, V. Vaeck, L. Mols, R. et al., Multidrug resistanceassociated protein 2 (MRP2) affects hepatobiliary elimination but not the intestinal disposition of tenofovir disoproxil fumarate and its metabolites, Xenobiotica, vol.35, pp.1055-66, 2005.

A. Colbers, D. A. Hawkins, A. Gingelmaier, K. Kabeya, J. K. Rockstroh et al., The pharmacokinetics, safety and efficacy of tenofovir and emtricitabine in HIV-1-infected pregnant women, AIDS Lond Engl, vol.27, issue.5, pp.739-787, 2013.

E. Valade, J. Tréluyer, F. Dabis, E. Arrivé, E. Pannier et al., Modified renal function in pregnancy: impact on emtricitabine pharmacokinetics: FTC population pharmacokinetics during pregnancy, Br J Clin Pharmacol, vol.78, issue.6, pp.1378-86, 2014.
DOI : 10.1111/bcp.12457

URL : http://europepmc.org/articles/pmc4256626?pdf=render

A. M. Stek, B. M. Best, W. Luo, E. Capparelli, S. Burchett et al., Effect of pregnancy on emtricitabine pharmacokinetics, HIV Med, vol.13, issue.4, pp.226-261, 2012.
DOI : 10.1111/j.1468-1293.2011.00965.x

URL : https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1468-1293.2011.00965.x

S. Benaboud, D. K. Ekouévi, S. Urien, E. Rey, E. Arrivé et al., Population pharmacokinetics of nevirapine in HIV-1-infected pregnant women and their neonates, Antimicrob Agents Chemother, vol.55, issue.1, pp.331-338, 2011.

M. A. Czuba, D. J. Morgan, M. S. Ching, G. W. Mihaly, K. J. Hardy et al., Ontogeny of fetal renal organic cation excretion: a study with cimetidine and ranitidine during the latter half of gestation in the pregnant ewe, J Pharmacol Exp Ther, vol.255, issue.3, pp.1177-82, 1990.

L. Biology and P. , Advances in Fetal and Neonatal Physiology: Proceedings of the Center for Perinatal Biology 40th Anniversary Symposium, vol.258, 2014.

W. M. Gilbert, P. S. Newman, E. Eby-wilkens, and R. A. Brace, Technetium Tc 99m rapidly crosses the ovine placenta and intramembranous pathway, Am J Obstet Gynecol, vol.175, issue.6, pp.1557-62, 1996.
DOI : 10.1016/s0002-9378(96)70106-0

W. M. Gilbert, C. Y. Cheung, and R. A. Brace, Rapid intramembranous absorption into the fetal circulation of arginine vasopressin injected intraamniotically, Am J Obstet Gynecol, vol.164, issue.4, pp.1013-1018, 1991.

G. Smith and A. D. Cameron, Estimating human fetal blood volume on the basis of gestational age and fetal abdominal circumference, BJOG Int J Obstet Gynaecol, vol.109, issue.6, pp.721-723, 2002.

V. Zanardo, C. Gabrieli, F. De-luca, D. Trevisanuto, D. Santis et al., Head-to-body delivery by ?two-step' approach: effect on cord blood hematocrit, J Matern-Fetal Neonatal Med Off J Eur Assoc Perinat Med Fed Asia Ocean Perinat Soc Int Soc Perinat Obstet, vol.26, issue.12, pp.1234-1242, 2013.
DOI : 10.3109/14767058.2013.776534

Y. Chang, Y. Wang, T. Lin, T. , Y. Chen et al., Complete Blood Count Reference Values of Cord Blood in Taiwan and the Influence of Gender and Delivery Route on Them, Pediatr Neonatol, vol.52, issue.3, pp.155-60, 2011.

M. Eskola, S. Juutistenaho, K. Aranko, S. Sainio, and R. Kekomäki, Association of cord blood platelet count and volume with hemoglobin in healthy term infants, J Perinatol, vol.31, issue.4, pp.258-262, 2010.

E. E. Ziegler, O. Donnell, A. M. Nelson, S. E. Fomon, and S. J. , Body composition of the reference fetus, Growth, vol.40, issue.4, pp.329-370, 1976.

W. S. Uttley and A. H. Habel, Fluid and electrolyte metabolism in the newborn infant, Clin Endocrinol Metab, vol.5, issue.1, pp.3-37, 1976.
DOI : 10.1016/s0300-595x(76)80006-0

R. S. Kuipers, M. F. Luxwolda, P. J. Offringa, R. Boersma, E. Dijck-brouwer et al., Fetal intrauterine whole body linoleic, arachidonic and docosahexaenoic acid contents and accretion rates, Prostaglandins Leukot Essent Fatty Acids, vol.86, issue.1-2, pp.13-20, 2012.
DOI : 10.1016/j.plefa.2011.10.012

J. F. Roux, Y. Takeda, and A. Grigorian, Lipid concentration and composition in human fetal tissue during development, Pediatrics, vol.48, issue.4, pp.540-546, 1971.

M. Mirochnick, T. Taha, R. Kreitchmann, K. Nielsen-saines, N. Kumwenda et al., Pharmacokinetics and Safety of Tenofovir in HIV-infected women during labor and their infants during the first week of life, JAIDS J Acquir Immune Defic Syndr, vol.65, issue.1, pp.33-41, 2014.

L. J. Else, S. Taylor, D. J. Back, and S. H. Khoo, Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the fetal compartment (placenta and amniotic fluid), Antivir Ther, vol.16, issue.8, pp.1139-1186, 2011.

H. Schneider, M. Panigel, and J. Dancis, Transfer across the perfused human placenta of antipyrine, sodium and leucine, Am J Obstet Gynecol, vol.114, issue.6, pp.822-830, 1972.

B. H. Jung, N. L. Rezk, A. S. Bridges, A. H. Corbett, and A. Kashuba, Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography-tandem mass spectrometry, Biomed Chromatogr, vol.21, issue.10, pp.1095-104, 2007.

K. Shintaku, Y. Arima, Y. Dan, T. Takeda, K. Kogushi et al., Kinetic Analysis of the Transport of Salicylic Acid, a Nonsteroidal Antiinflammatory Drug, across Human Placenta, Drug Metab Dispos, vol.35, issue.5, pp.772-780, 2007.

N. Simon, Analyse pharmacocinétique et pharmacodynamique par approche de population. Estimation, évaluation, simulation

. Solal, Available from: about:home, 2011.

M. L. Lindstrom and D. M. Bates, Nonlinear mixed effects models for repeated measures data, Biometrics, vol.46, issue.3, pp.673-87, 1990.
DOI : 10.2307/2532087

E. Kuhn and M. Lavielle, Coupling a stochastic approximation version of EM with an MCMC procedure, ESAIM Probab Stat, vol.8, pp.115-131, 2004.

N. Holford, VPC, the visual predictive check-superiority to standard diagnostic(Rorschach) plots, 2005.

R. A. Corley, M. J. Bartels, E. W. Carney, K. K. Weitz, J. J. Soelberg et al., Development of a Physiologically Based Pharmacokinetic Model for Ethylene Glycol and Its Metabolite, Glycolic Acid, in Rats and Humans, Toxicol Sci, vol.85, issue.1, pp.476-90, 2005.

T. M. Mayhew, Morphomics: An integral part of systems biology of the human placenta, Placenta, vol.36, issue.4, pp.329-369, 2015.

M. R. Syme, J. W. Paxton, and J. A. Keelan, Drug transfer and metabolism by the human placenta, Clin Pharmacokinet, vol.43, issue.8, pp.487-514, 2004.